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HEADACHE CURRENTS

Basic Considerations for the Use of Monoclonal Antibodies in Migraine
Morris Levin, MD; Stephen D. Silberstein, MD; Robert Gilbert, MD; Sylvia Lucas, MD, PhD; Leanne Munsie, BS;
Alyssa Garrelts, PhD; Kate Kennedy, MN; Nicole Everman, MD; Eric Pearlman, MD, PhD
and 1 billion people worldwide.2 Migraine has a substantial impact on patients’ physical, social, and occupational functioning,
as well as health care expenses and lost productivity of up to $36
billion annually in the United States.2 Despite the increasing
availability of acute and preventive therapies, there remains a
high unmet need.2,3 For example, while 38.8% of people with
migraine would benefit from preventive treatment, only 5-13%
receive it.4,5 Potential treatments under development include
monoclonal antibodies (mAbs).3 Appropriate use of these biologic treatments will necessitate an understanding of the aspects
that distinguish them from traditional medications.

Background.—Migraine impacts more than 36 million
people in the United States and 1 billion people worldwide.
Despite the increasing availability of acute and preventive
therapies, there is still tremendous unmet need. Potential
treatments in development include monoclonal antibodies
(mAbs). Appropriate use of these “biologic” treatments will
necessitate an understanding of the aspects that distinguish
them from traditional medications.
Aim.—Many drug classes are prescribed for migraine treatment,
but all have limitations. Recently, calcitonin gene-related peptide
(CGRP) activity has shown a significant promise as a target for
preventive therapy. In this review, we provide an overview of the
potential role of CGRP mAbs in migraine, with a focus on their
design, pharmacokinetics, safety, and immunogenicity.
Conclusions.—The CGRP mAbs are an innovative new
therapy for migraine and address the need for effective and
tolerable preventive options. MAbs, including those that target
CGRP or its receptor, bind to a target with high specificity and
affinity and lead to few off-target adverse effects, although
mechanism-based adverse reactions may occur. Unlike other
therapeutic antibodies used to treat neurologic disease, CGRP
mAbs do not have a target within the immune system and have
been designed to avoid altering the immune system. The safety
and efficacy of mAbs against CGRP or its receptors are being
investigated in clinical development programs, and the first of these
therapies has received regulatory approval in the United States.

DISCUSSION/OBSERVATIONS

Key words: migraine, CGRP, therapeutic antibodies, anti-CGRP
mAbs for migraine

INTRODUCTION

Migraine is a common disabling primary headache disorder
that affects more than 36 million people in the United States1
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Treatment Targets for Migraine
The pathophysiology of migraine is being actively explored
and better understood. Evidence supports that migraine is a
neurobiological disorder that arises from disturbances of cortical and/or brainstem activity, including cortical spreading
depression (CSD), activation of the trigeminovascular system,
neurogenic inflammation, and central sensitization.6,7
Many drug classes are prescribed for migraine treatment,
but the only currently available medication class specifically
developed to treat migraine is the triptan class. Triptans primarily target 5-HT1B/1D receptors as agonists for acute treatment. It is believed that triptans abort a migraine attack by
modulating trigeminal nociceptive pathways, in part by
inhibiting calcitonin gene-related peptide (CGRP) release
through activation of serotonin receptors.5,7 Other acute and
preventive treatments were appropriated from other medical
indications, and their mechanisms of action are less well understood.8 Many are associated with low tolerability and poor
1-year adherence rates.5,9
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Improved understanding of migraine pathophysiology has
led to therapies with novel targets (eg, selective 5-HT1F receptors, the SP-NK1R system, CGRP, nitric oxide synthase, glutamate receptors).3,10 The CGRP molecule is currently the focus
of therapies in development for migraine prevention. It is the
most abundant neuropeptide in the trigeminal nerve and seems
intimately linked to migraine pathogenesis.11 MAbs targeting
CGRP or its receptor are the only therapies specifically designed
for prevention of migraine.3,8 In preparation for these developments, we provide an overview of the role of CGRP in migraine
and a discussion of mAbs, including their design, pharmacokinetics, safety, and interpretation of immunogenicity data.
CGRP
CGRP is a 37-amino acid peptide with 2 isoforms, α and β,
that differ by only 3 amino acids. CGRPα is present primarily in central and peripheral nervous system, and β is primarily
found in enteric sensory neurons. Both isoforms are complete
agonists of the CGRP receptor. Specific to the CNS, CGRP is
apparently involved in pain modulation, perception, and central sensitization, making it a potential target for migraine and
other primary headache disorders. CGRP also has expression in
non-neuronal tissues. It is a potent vasodilator and has a variety
of additional biological effects, including on cardiac, smooth,
and skeletal muscle; skin; the endocrine system; and the gastrointestinal system.11–13
CGRP binds strongly to both the canonical CGRP receptor (composed of the calcitonin receptor-like receptor [CLR]
and receptor activity-modifying protein 1 [RAMP1]); and the
amylin 1 (AMY1) receptor (formed by a complex of the calcitonin receptor [CTR] with RAMP1). Binding of the ligand
CGRP to CGRP receptors activates multiple intracellular pathways, including adenylyl cyclase and the cyclic adenosine monophosphate (cAMP)‒signaling pathway. Association of receptor
component protein (RCP) with the CGRP receptor is important
for optimal signal transduction. CGRP binds with lower affinity
to adrenomedullin receptors (formed by CLR and RAMP2 [adrenomedullin 1 {AM1} receptor] or CLR and RAMP3 [AM2]
receptor) and other amylin receptors (formed by calcitonin receptor and RAMP2 [AMY2] or RAMP3 [AMY3]).11,13,14
There is compelling evidence of the involvement of CGRP
in migraine pathophysiology.3,8 CGRP is elevated in external
jugular venous blood during a migraine attack and in peripheral
blood of patients who experience migraines even when they are
not experiencing a migraine attack.15 Additionally, intravenous
CGRP infusion into people with migraine can trigger migraine
symptoms.16,17
In migraine pathophysiology, activated trigeminal nerves
release CGRP, other vasoactive peptides such as vasoactive
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intestinal peptide, and classic neurotransmitters, like serotonin,
that cause the subsequent release of proinflammatory mediators.13 These mediators further increase CGRP synthesis and
release over hours to days, corresponding to the 4- to 72-hour
duration of a typical migraine episode.15 Additionally, amelioration of migraine pain after treatment with sumatriptan correlates to the return of CGRP levels to normal after elevation
during the migraine attack.18 See Figure 1 for a schematic of the
proposed role of CGRP in migraine pathophysiology.
A role for targeting CGRP in migraine has been established
through clinical trials of various CGRP-targeting therapies.
Initially, CGRP was targeted for the acute treatment of migraine with small-molecule CGRP antagonists (gepants). These
therapies offered efficacy similar to published results for some
oral triptans, but initial development programs were halted due
to observed hepatotoxicity associated with some of these drugs.
However, new gepants are in development.19
Most recently, mAbs with CGRP-modulating effects show
a significant benefit in patients with episodic and chronic
migraine.20-24
Antibodies and Therapeutic Antibodies
Endogenous antibodies are produced when B cells are activated after they encounter an antigen, and then mature into
plasma cells that produce a specific antibody to that particular antigen.8,25,26 Immunoglobulin G (IgG) makes up 70%
of all immunoglobulins and accounts for the majority of antibody-based immunity against invading pathogens.25 Human
IgG consists of 4 subclasses (isotypes), which are numbered in
order of decreasing serum concentrations (IgG1, IgG2, IgG3,
and IgG4).25,26 The 4 subclasses share 90% identity of overall amino acid sequence and are identical in the constant regions.26,27 Antibody structure is shown in Figure 2.
While endogenous antibodies function to present foreign
substances to the immune system in order to clear them and
activate the immune system, it is possible to engineer mAbs –
made from one clone of plasma cells – with high specificity.
Because of this, mAbs are promising therapeutic candidates for
many diseases.28 Approved mAb therapies currently exist for
a number of diseases, such as rheumatoid arthritis or multiple
sclerosis.28,29 Highly effective therapeutic mAbs have been used
since 1985 (muromonab-CD3 for transplant rejection).30 At
the time of writing, of 81 US Food and Drug Administration
(FDA)-approved therapeutic mAbs, only 6 are available for
indications other than oncology, autoimmune, or infectious
disease, and only 3 are non-immunomodulatory therapies for
chronic disease (PCSK9 inhibitors evolocumab and alirocumab
to treat hypercholesterolemia, and Factor IX/X inhibitor emicizumab for the treatment of hemophilia A).29
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Fig. 1.—Calcitonin gene-related peptide (CGRP) in migraine. CGRP may contribute to migraine by affecting: (A) Neurogenic inflammation;
(B) blood flow in cerebral vessels; and (C) pain transmission. [Color figure can be viewed at wileyonlinelibrary.com] [Correction added after
first online publication on November 26, 2018: Figure swapped with Figure 2.]

Since they are foreign substances, therapeutic mAbs may induce an immune response. Initial therapeutic antibodies were
produced from murine hybridomas (the fusion of murine myeloma cells and B cells to generate fusion cell lines with unique
specificity); however, due to their high murine sequence content,
they had high immunogenicity and short half-lives, which limited their application and led to the search for alternatives.28,31
Currently, multiple methods, such as transgenic mice, complementarity-determining region grafting, and phage display techniques, are used for the commercial production of humanized or
human mAbs (sequences either closely resemble or are identical
to human Ig sequences), which reduces immunogenicity.32,33
Importantly, although mAbs are engineered to reduce immunogenicity,34 some mAbs are specifically designed to
target molecules within the immune system (eg, mAbs for
autoimmune diseases) and thereby induce an immunologic effect.28 Others, such as recently developed anti-CGRP mAbs,
have been engineered to bind to either the CGRP peptide or

receptor with high specificity and thus have minimal interaction with the immune system.8 In contrast to mAbs that are
designed to bind immune cells or molecules in the immune
system (eg, mAbs indicated for multiple sclerosis), mAbs that
are engineered to target molecules outside the immune system
(eg, mAbs targeting CGRP and its receptor) have no immunomodulatory effect.
Therapeutic mAbs differ from small-molecule drugs in several ways that provide them with unique advantages and disadvantages (Table 1).8 MAbs primarily have extracellular targets,
while small molecules can have both extracellular and intracellular targets.8,35 The high target specificity (and thus reduced
chance for off-target effects) and long half-life of mAbs give
them a benefit over small molecules, especially in the treatment
of chronic diseases like migraine.28,35 However, they need to be
administered parenterally and, as noted, are potentially immunogenic.35 Advances in mAb engineering may help to further
enhance target specificity and reduce immunogenicity.36
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Fig. 2.—Structure of Ig. Antibodies are composed of 2 identical heavy and light chains that join to form the characteristic “Y” shape. The light
chain contains 1 variable domain and 1 constant domain. The heavy chain contains 1 variable domain and 3 constant domains. Each antibody
has an Fc region – the stem of the “Y,” which determines the effector function – and a Fab domain, the arms of the “Y.” The variable domains
of each chain include a framework region and 3 CDRs, also referred to as hypervariable regions. The set of CDRs constitutes the paratope, the
antigen-binding site that recognizes the epitope of a specific antigen. IgG (~150,000 Da) is shown next to aspirin (~180 Da) for a comparison
between antibodies and small molecules. CH = heavy chain constant; CL = light chain constant; FV = variable fragment; VH = heavy chain
variable; VL = light chain variable. [Color figure can be viewed at wileyonlinelibrary.com] [Correction added after first online publication on
November 26, 2018: Figure swapped with Figure 1.]

IgG is the most common Ig class and is used as the backbone for therapeutic antibodies.29 Endogenous IgG isotypes
have differing characteristics, but these differences may not
be relevant to engineered antibodies. Regardless of the choice
of subclass backbone, generation of highly specific and potent
mAbs involves engineering the fragment crystallizable (Fc) region of the IgG to minimize effector cell activity and maximize manufacturability, as well as engineering the variable
regions to further improve therapeutic properties, and limit
immunogenicity.36
Antibody Pharmacokinetics
Currently, mAbs are delivered through parenteral routes of
administration, primarily intravenous (IV) and subcutaneous
(SC), because of their large size and hydrophilicity, which limit
absorption from the gastrointestinal epithelium. In addition,
they have a high propensity to denature in the stomach and
degrade in the gastrointestinal tract.31,37
Peak concentrations achieved with parenteral extravascular
routes of administration are lower than those achieved with IV
routes.31 Absorption into systemic circulation for extravascular
routes occurs through the lymphatic system, and the slow flow

rate of lymph flow results in relatively slower absorption following SC injections, taking approximately 2-8 days to reach peak
plasma concentrations.31 However, since half-lives of mAbs may
be considerably longer than the time to peak concentration,31
differences between SC and IV routes are likely only clinically
relevant for applications where rapid systemic circulation or
high concentrations are required.
Antibodies are largely confined to the vasculature; they likely
reach their target tissues through extravasation via convective
transport.31 IgG concentration in the brain relative to plasma
is low (~1:500) due to the size of the molecule, inefficient convection uptake to the brain, rapid turnover of brain interstitial
fluids, and, perhaps, the active efflux of antibodies from the
brain tissue by Fc receptors (FcRns).31
MAbs are large molecules, so they are not filtered by the
kidney for excretion into the urine as intact molecules. MAbs
are catabolized by phagocytes (eg, macrophages, monocytes) of
the reticuloendothelial system (RES) into peptides and amino
acids. They may also be eliminated by target-mediated routes
through internalization within the target-expressing cells and
through intracellular breakdown within the lysosome or nonspecific endocytosis/pinocytosis.8,31
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Table 1.—Summary of Comparison of Small-Molecule Drugs and Antibody Therapies
Monoclonal Antibodies

Small-Molecule Drugs

Target specificity

High

Lower

Size

High MW (~150,000 g/mol)

Low MW (<0.9 g/mol)

Molecule

Protein

Chemical

Targets

Extracellular

Intracellular/extracellular

Primary administration

Parenteral

All routes

Half-life (t1/2)

Long; often days to weeks

Short; often hours

Dosing frequency

Every other week to yearly

Often dosed ≥1 time per day

Drug-drug interactions

Rare

Many examples

Metabolism pathway

Catabolism; degraded to peptides or amino acids

Mainly by CYP and phase II enzymes; metabolized to nonactive and active metabolites

Excretion

Mostly recycled as peptide fragments by the body

Liver, kidney

Potential for immunogenicity

Yes

No

API/production process

Culture derived

Synthesized

API = active pharmaceutical ingredient; CYP = cytochrome P450; MW = molecular weight.

The main factor that influences the half-life of therapeutic
mAbs is the interaction of the IgG with the neonatal FcRn on
the cell surface. The long half-life of endogenous antibodies is
the consequence of antibody salvage from lysosomal degradation by FcRn. MAbs can be engineered with increased halflives by alteration of the IgG Fc amino acids.28,31,38 The average
serum half-life of therapeutic IgG varies widely but is much
longer than that of small-molecule drugs, allowing them to be
administered with typical frequencies ranging from every other
week to yearly.29
Factors that affect antibody pharmacokinetics include the
properties of the antibody (eg, origin, structure, size, concentration, and affinity), properties of the antigen or target (eg, distribution, concentration), and patient characteristics (eg, body
mass index, sex, age, activity level).28
MAbs targeting CGRP and its receptor have pharmacokinetic properties typical of other therapeutic antibodies. Hence,
they are administered parenterally with frequencies ranging
from monthly to quarterly.39
Antibody Safety
Safety risks associated with mAbs can be divided into 2 major
categories: on-target and off-target. On-target modulation may
cause adverse effects or potential safety concerns because of
downstream effects related to intended activity. For example,
in therapies approved for treatment of multiple sclerosis, some
mAbs target the immune system directly by binding to sites on
T cells or B cells. While these treatments have shown high efficacy related to modulation of the immune system, the same
modulation may increase the risk of unwanted effects (eg, opportunistic infections or malignancies) resulting from the change

in immune response.34,40 Target-based toxicities may also arise
for therapies with targets other than immunomodulation. For
example, mAbs used for various cancers may cause dermatological toxicity, cardiotoxicity, and bleeding complications resulting from the modulation of EGFR, HER2, and angiogenesis,
respectively.8 Since CGRP is involved in many organ systems,
there is the potential for target-related adverse events. These
could conceivably include unwanted effects on systems related
to cardiovascular, gastrointestinal, endocrinological, and wound
healing function. However, clinical trials of mAbs intended to
modulate CGRP showed no clinically meaningful differences
between the active treatment arms and the placebo arms for
the results of hepatic-function testing, creatinine levels, total
neutrophil counts, vital signs, or electrocardiographic findings
during the treatment periods.20-24 Moreover, patient-reported
adverse effects have generally differed minimally between active
and placebo groups in clinical studies. Patients with diseases affecting relevant organs are typically excluded from clinical trials; therefore, the effects of CGRP modulation in these patients
are unknown.
Because of their high specificity, there is low risk of mAbs
nonspecifically binding to unintended cells or tissues, causing
off-target-related adverse events.8 For example, to achieve their
intended result of lowering low-density lipoprotein (LDL) levels, PCSK9 inhibitors bind to and neutralize PCSK9, which
in turn prevents reabsorption of the LDL receptor, resulting
in a dramatic lowering of LDL. These therapies demonstrate
excellent safety profiles (with essentially no off-target adverse
effects), in addition to improved cardiovascular outcomes.41
CGRP-modulating mAbs have so far reported similarly low
risks of off-target-related toxicities.3,39
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Due to technical advances, it is now possible to produce
mAbs with very little antigenic material (ie, little to no murine components).32,33 As a result, serious off-target immunogenic adverse effects, such as anaphylaxis and serum sickness
that affected early murine mAbs, have been dramatically
minimized, as discussed below (Immunogenicity section).
Off-target effects for modern mAbs relate more to tolerability
and are most commonly associated with route of administration, resulting, for example, in injection site reactions with SC
administration, which may include swelling, itching, redness,
and pain. An IV route is less likely to cause injection site reactions since it is delivered directly into the vascular system.8,34
Clinical trial results of CGRP-modulating mAbs indicate
that treatment-emergent adverse events that investigators considered possibly related to treatment were not significantly different among the active treatment and placebo groups. Adverse
events that occurred were largely reactions at the injection site
in those mAbs subcutaneously administered.20-24
Since IgG is known to be transported into the placenta by
the FcRn, and a significant portion of migraine patients are
women of reproductive age, safety considerations in pregnancy
will need further study.2,26 Additionally, since clinical trials for
these mAbs were up to 12 months in duration, the long-term
safety of CGRP modulation has not been established.20-24
Immunogenicity
As with all therapeutic biologics, mAbs may be recognized
as foreign, resulting in an immune response and the creation
of antidrug antibodies (ADAs).8 This immunogenicity is influenced by both drug- and patient-related factors.42 The clinical consequences of ADAs may range from no apparent effect
to loss of efficacy, alteration of half-life, or, rarely, significant
adverse effects.8,43 ADAs are termed non-neutralizing if they
are directed against the non-antigen-binding region and do not
affect binding of the therapeutic antibody to its target. They
are neutralizing if they are directed against the portion of the
variable region of the antibody that confers antigen specificity
or interfere with target binding.43
Immunogenicity was long felt to be only associated with
the fraction of foreign sequence in the therapeutic antibody.
However, it has recently become apparent that immunogenicity of therapeutic mAbs also arises from immune responses directed against the variable regions of the mAb.44 Human and
humanized antibodies carry a lower risk for inducing immune
responses in humans than mouse or chimeric antibodies, but
even human sequence-derived antibodies can induce ADAs.42-44
While International Nonproprietary Name conventions previously dictated that the portion of murine-derived material be specified with a source infix (eg -xi-, -zu-), new mAb
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nomenclature guidance discontinues the use of the source infix,
emphasizing the observation that human and humanized mAbs
do not substantially vary in immunogenicity and that this
should not be used as a differentiator between mAbs.45
Measurement of and subsequent clinical implications of
ADAs vary among products. Detection of ADA formation
is highly dependent on the sensitivity and specificity of the
assay, and the observed incidence of ADAs may be influenced
by factors such as method, sample handling, timing of sample
collection, concomitant medications, and disease condition.
Therefore, the FDA cautions against comparison of ADA
incidence between different mAbs, even for products that
share sequence or structural homology.44 Further, while endogenous antibodies are generally present in concentrations
of approximately 10 mg/mL, and most therapeutic mAbs are
administered at concentrations <10 µg/mL,31 FDA guidance
mandates that assays for ADAs should have detection limits
of <100 ng/mL.44 Thus, detection of ADAs does not imply
any clinical effect.8 Further complicating the interpretation
of ADA results, literature suggests that even patients who are
naive to a therapy can have preexisting ADAs to that therapy.44 Moreover, while incidence of ADAs and neutralizing
ADAs is generally reported, especially in product labeling,
the clinical impact of ADAs may be associated with ADA
titer and persistence rather than incidence.44 Therefore, when
considering ADAs in the clinical context, it is the clinical
effect which is of true importance. If there is no change in
efficacy or safety, the presence of ADAs is of no clinical importance.8 Reported data for ADAs for CGRP-modulating
mAbs are limited, but no impact of ADA development on
efficacy or safety has been demonstrated.46
Summary
Anti-CGRP mAbs are an innovative new therapeutic class
for migraine. They address the significant need for more efficacious and tolerable preventive options. They are the first preventive therapies designed specifically for migraine.
The promise of CGRP-targeting therapies was first demonstrated by small-molecule therapies targeting the CGRP receptor. These were shown to be highly efficacious in acute
treatment of migraine, with efficacy comparable to that in the
best published reports of oral triptans. However, the early gepants caused hepatotoxicity, and newer gepants will have to be
assessed carefully.
At the time of writing, several mAbs targeting either the
CGRP ligand or receptor are in development, and 3 have been
approved by the FDA. In contrast with small molecules, mAbs
have low potential for off-target effects, and have long halflives, making them good candidates for chronic diseases like
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migraine. Importantly, unlike small molecule drugs, mAbs are
degraded and eliminated like endogenous IgGs via the RES
rather than through metabolic pathways. Therefore, mAbs
targeting CGRP or its receptor are not expected to induce the
hepatotoxicity seen with the initial gepants. However, CGRP
mAbs need to be administered parenterally, and consideration
should be given to the potential risks associated with that route.
While mAbs targeting CGRP or its receptor bind to their
targets with high specificity and affinity, leading to few off-target adverse effects, it is important to keep in mind that mechanism-based toxicities may occur. These might involve vascular,
gastrointestinal, and other systems, but, to date, modulation of
CGRP has been shown to cause only limited target-related toxicities. Additionally, CGRP mAbs do not have a target within the
immune system and have been designed to avoid alteration of
the immune system, distinguishing them from other therapeutic
antibodies currently approved to treat neurologic diseases.
As with all mAbs, immunogenicity may occur with mAbs
targeting CGRP or its receptor, leading to formation of ADAs.
Potential clinical effects of ADAs include loss of response, as
well as hypersensitivity or allergic reactions. If there is no change
in efficacy or safety, the presence of ADAs is of no clinical importance. Since ADAs largely arise from immune response to
the variable regions of mAbs, clinical differences in ADA effects between humanized and human mAbs are not expected.
The translation of ADA data to clinical practice is challenging
due to factors such as inability to adequately compare ADA incidence between mAbs, and the reporting of ADA incidence
rather than titer and persistence.

KEY CONCLUSIONS
1. The safety and efficacy of mAbs against CGRP or its
receptors are currently being investigated in clinical development programs, and the first group of these therapies
has recently been approved.
2. Over time, we will understand the long-term safety of these
mAbs, but the therapeutic benefit of this new class of migraine treatment is promising for patients with inadequately
controlled migraine.
3. It is important for clinicians to understand the aspects of
these non-immunomodulatory mAb therapies that distinguish them from small-molecule therapies and other types of
therapeutic mAbs.
Acknowledgments: The authors wish to thank Dr. Michael
Hodsdon for providing valuable insights about antidrug antibodies. FORCE Communications provided editorial and
graphics support in the preparation of this manuscript.
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